Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 31, 2116-2119, December 1, 1971]
© 1971 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ogawa, M.
Right arrow Articles by McCulloch, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ogawa, M.
Right arrow Articles by McCulloch, E. A.

Differential Effects of Melphalan on Mouse Myeloma (Adj. PC-5) and Hemopoietic Stem Cells1

Makio Ogawa2, Daniel E. Bergsagel and E. A. McCulloch

Department of Medicine, University of Toronto, and The Ontario Cancer Institute, Toronto, Ontario, Canada

The effect of melphalan on mouse myeloma and hemopoietic progenitor cells was studied with a primary cell culture assay for mouse myeloma stem cells developed by Park, Bergsagel, and McCulloch and bone marrow cell culture and spleen colony assays for hemopoietic progenitor cells. Myeloma and bone marrow cells were exposed in vivo to graded doses of melphalan and harvested 3 and 24 hr later for assays of the surviving fractions. The sensitivity of myeloma cells was more than 70 times greater than that of normal bone marrow cells. Exposure of the 2 cell classes to melphalan in culture also showed a similar differential effect of melphalan.

The sensitivity of normal and regenerating bone marrow to melphalan was almost identical when assayed by cell culture or the spleen colony method. These results indicate that the sensitivity of hemopoietic progenitor cells to melphalan is not influenced by the proliferative state of these cells. It would appear that the vast difference in the sensitivity of these 2 cell classes to melphalan is dependent on intrinsic differences between myeloma stem cells and hemopoietic progenitor cells.

1 This investigation was supported by a grant from The Ontario Cancer Treatment and Research Foundation.

2 Research Fellow of The Ontario Cancer Treatment and Research Foundation.

Received 7/28/71. Accepted 8/19/71.




This article has been cited by other articles:


Home page
ScienceHome page
A. Hamburger and S. Salmon
Primary bioassay of human tumor stem cells
Science, July 29, 1977; 197(4302): 461 - 463.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1971 by the American Association for Cancer Research.